In summary, this study has demonstrated that the curcumin analogue GO-Y030 effectively inhibits p300-HAT activity and ameliorates TAC-induced progression of cardiac hypertrophy and heart failure at much lower doses than the natural compound curcumin. The gene discussed is EP300; the disease is heart failure.